TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15026612

Group type: EXPERIMENTAL
Intervention: 30 mg of aspirin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 mg of aspirin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 75 mg of aspirin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg of aspirin (AIS subgroup)
Number of subjects: 60
Study: 11576461

Group type: EXPERIMENTAL
Intervention: IFN-alpha (5 MU/m2 body surface subcutaneously three times per week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (CAH B, not treated with IFN-alpha)
Number of subjects: 44
Study: 9521254

Group type: EXPERIMENTAL
Intervention: Tacrine (80, 120, or 160 mg/day)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study: 8005126

Group type: EXPERIMENTAL
Intervention: Anaerobic threshold (AT) determination using various methods (RER, carbon dioxide, minute ventilation, ventilatory equivalents)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Crossing point method for AT determination
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Peak oxygen uptake assessment
Number of subjects: 85
Study: 30829979

Group type: EXPERIMENTAL
Intervention: Diagnostic readiness tests (DRTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ACP clinical placements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment, diagnosis, management, and pharmacology domains
Number of subjects: 0
Study: 31618910

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 5 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 28556689

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temsirolimus
Number of subjects: 0
Study: 26377150

Group type: EXPERIMENTAL
Intervention: Nordic Cochrane Centre information on BCS
Number of subjects: 355

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 355
Study: 23302821

Group type: EXPERIMENTAL
Intervention: Acupressure treatment (9-minute daily for 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard medical care (Control group)
Number of subjects: 60
Study: 19034054

Group type: EXPERIMENTAL
Intervention: Combined vaginal and oral low‐dose estrogen plus progestogen therapy (EPT)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 17452842

Group type: EXPERIMENTAL
Intervention: Liposomal melanin spray (Lipoxome) with 3 cycles of 800 nm diode laser at intervals of 8 weeks (28-40 J/cm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physiological saline spray before diode laser treatment
Number of subjects: 16
Study: 15050312

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg i.v. 20‐30 min before treatment the first 2 days of each week)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (thoracic RT plus oral etoposide and cisplatin without amifostine)
Number of subjects: 62
Study: 11952193

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Patterns of depressive symptoms
Number of subjects: 163
Study: 10221371

Group type: EXPERIMENTAL
Intervention: Digital monitor
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Aneroid monitor
Number of subjects: 99

Group type: COMPARATOR
Intervention: Desktop mercury sphygmomanometer (DMS)
Number of subjects: 99
Study: 7529489

Group type: EXPERIMENTAL
Intervention: 1 mg/day finasteride
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg/day finasteride
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 2145236

Group type: EXPERIMENTAL
Intervention: Enoximone (1 mg/kg bolus, every 8 hours for 48 hours)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional therapy (frusemide, nitrates, dopamine‐dobutamine)
Number of subjects: 44
Study: 438356

Group type: EXPERIMENTAL
Intervention: 8 mg loperamide HCl (syrup formulation)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 8 mg loperamide HCl (capsule formulation)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparative analysis of syrup and capsule formulations
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Excretion of unchanged loperamide
Number of subjects: 6
Study: 30267699

Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% twice daily for 4 weeks
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% four times daily for 4 weeks
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% four times daily for 8 weeks
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 28853994

Group type: EXPERIMENTAL
Intervention: Whole red grape juice (150 ml for men and 100 ml for women)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Whole red grape juice
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 26
Study: 25955226

Group type: EXPERIMENTAL
Intervention: PTH (1-84) 100 μg/d
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 23685057

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 17
Study: 21856809

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2-g loading dose followed by 500 mg every 12 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19707219

Group type: EXPERIMENTAL
Intervention: Mediterranean diet rich in virgin olive oil
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Mediterranean diet rich in nuts
Number of subjects: 187

Group type: COMPARATOR
Intervention: Conventional low‐fat diet (control)
Number of subjects: 187
Study: 17548664

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 15114031

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy (RPL-IVIg); 500 mg IVIg/kg/month
Number of subjects: 15

Group type: COMPARATOR
Intervention: Multivitamin (placebo)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal pregnant women without APS
Number of subjects: 15
Study: 15771407

Group type: EXPERIMENTAL
Intervention: Corticoamygdalohippocampectomy
Number of subjects: 100
Study: 9643400

Group type: EXPERIMENTAL
Intervention: Labour group (73 patients)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Elective caesarean section group (45 patients)
Number of subjects: 118
Study: 7911416

Group type: EXPERIMENTAL
Intervention: Litmus paper
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intragastric pH probes
Number of subjects: 0
Study: 2510255

Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 4940157

Group type: EXPERIMENTAL
Intervention: Immunotherapy (B.C.G.)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Intermittent methotrexate
Number of subjects: 191

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 191
Study: 31332110

Group type: EXPERIMENTAL
Intervention: Single-pass technique for lenticule preparation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Double-pass technique for lenticule preparation
Number of subjects: 20
Study: 28445471

Group type: EXPERIMENTAL
Intervention: Concise consent form
Number of subjects: 4229

Group type: COMPARATOR
Intervention: Standard consent form
Number of subjects: 4229
Study: 26102258

Group type: EXPERIMENTAL
Intervention: Medicine Ball Training (MBT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 28
Study: 24444439

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day)
Number of subjects: 122
Study: 22967451

Group type: EXPERIMENTAL
Intervention: EC-T (epirubicin 90 mg/m², cyclophosphamide 600 mg/m² for 4 cycles, followed by docetaxel 80 mg/m² for 4 cycles)
Number of subjects: 95

Group type: COMPARATOR
Intervention: TP (docetaxel 75 mg/m², carboplatin AUC = 5 for 6 cycles)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: EC-T
Number of subjects: 95

Group type: COMPARATOR
Intervention: TP
Number of subjects: 95
Study: 19645218

Group type: COMPARATOR
Intervention: LTG
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: LTG + VPA
Number of subjects: 38
Study: 17294378

Group type: EXPERIMENTAL
Intervention: Continuous full-time occlusion of the sound eye (24 hours per day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Full-time occlusion of the sound eye 1 day more than the years of age, periodically alternating with occlusion of the amblyopic eye for 1 day
Number of subjects: 53
Study: 16039494

Group type: EXPERIMENTAL
Intervention: Topical pilocarpine 4%
Number of subjects: 14

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 14
Study: 12460124

Group type: EXPERIMENTAL
Intervention: Cannabis Youth Treatment (CYT) study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marijuana Treatment Project (MTP)
Number of subjects: 0
Study: 9877359

Group type: EXPERIMENTAL
Intervention: Td vaccine in Grade 6 students
Number of subjects: 410

Group type: COMPARATOR
Intervention: Td vaccine in Grade 9 students
Number of subjects: 410
Study: 7795925

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 2612430

Group type: EXPERIMENTAL
Intervention: Group A - standard brief description of upper G-I endoscopy
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Group B - detailed description by the endoscopist
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Group C - comprehensive explanation with pictures
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Group D - specially prepared video film of the procedure
Number of subjects: 243

Group type: COMPARATOR
Intervention: Group E - patients who had previously undergone upper gastrointestinal endoscopy
Number of subjects: 243
Study: 359245

Group type: EXPERIMENTAL
Intervention: 500 mg diflunisal twice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: 25 mg codeine phosphate 4-times daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31954884

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional perioperative care (control group)
Number of subjects: 94
Study: 30100316

Group type: EXPERIMENTAL
Intervention: Cryostretching
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 37
Study: 26386383

Group type: EXPERIMENTAL
Intervention: Endoscopic repair of OSB using a biocellulose patch
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Endoscopic repair of OSB
Number of subjects: 10
Study: 24968955

Group type: COMPARATOR
Intervention: COT1 (45 hours of conventional occupational therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: COT2 (80 hours of conventional occupational therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FES + COT (40 hours of COT therapy + 40 hours of FES therapy)
Number of subjects: 0
Study: 23156041

Group type: EXPERIMENTAL
Intervention: Hypoxen (antioxidant)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Routine therapy (Control)
Number of subjects: 391
Study: 20510800

Group type: EXPERIMENTAL
Intervention: Repeat back (RB) method
Number of subjects: 575

Group type: COMPARATOR
Intervention: Standard (STD) iMedConsent
Number of subjects: 575
Study: 18978404

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty
Number of subjects: 199

Group type: COMPARATOR
Intervention: Arthrodesis
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty and arthrodesis
Number of subjects: 199
Study: 16102611

Group type: EXPERIMENTAL
Intervention: Open Repair (OR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Endovascular Therapy (ET)
Number of subjects: 30
Study: 11957554

Group type: EXPERIMENTAL
Intervention: Daily regimen (2HRZ/2HR) - 2 months of isoniazid (H), rifampicin (R) and pyrazinamide (Z), followed by 2 months of H and R
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Combined regimen (2HRZ/2H3R3) - 2 months of HRZ, followed by H and R given 3 times weekly for 2 months or 4 months if initial sputum specimens were culture positive
Number of subjects: 314
Study: 10617009

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional on-pump surgery
Number of subjects: 200
Study: 8951267

Group type: EXPERIMENTAL
Intervention: CNS/NP team
Number of subjects: 821

Group type: COMPARATOR
Intervention: Pediatric resident team
Number of subjects: 821
Study: 1957749

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 1444
Study: 7137874

Group type: EXPERIMENTAL
Intervention: Conventional metoprolol 100 mg twelve hourly
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol S.A. (slow release formulation) once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxprenolol S.R. (slow release formulation) once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol S.A.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxprenolol S.R.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31182369

Group type: EXPERIMENTAL
Intervention: Inhaled eluforsen (up to 50 mg, dosed 3 times per week for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31852085

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP) adherence
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: African American
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Incident chlamydia
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Receiving items for sex
Number of subjects: 392
Study: 27367473

Group type: EXPERIMENTAL
Intervention: Computer-based education (CBE) program at home
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (standard teaching)
Number of subjects: 246
Study: 24326480

Group type: EXPERIMENTAL
Intervention: Lecture-based CPE
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Workshop-based CPE
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120
Study: 24438599

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 μg/kg intravenously for 10 minutes, maintained with 0.4 μg/kg and modulated from 0.2 to 0.7 μg/kg/hour in ICU
Number of subjects: 66

Group type: COMPARATOR
Intervention: Propofol 0.1 mg/kg intravenously for 10 minutes, maintained with 1 to 2 mg/kg/hour in recovery room and ICU
Number of subjects: 66
Study: 23062388

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with higher serum level of 25(OH)D
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with 25(OH)D serum level higher than 30 ng/mL
Number of subjects: 36

Group type: COMPARATOR
Intervention: Allergen immunotherapy
Number of subjects: 36
Study: 19442372

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration cytology (USFNAC)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional palpation-guided fine-needle aspiration cytology (PFNAC)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: USFNAC
Number of subjects: 112

Group type: COMPARATOR
Intervention: PFNAC
Number of subjects: 112
Study: 17635283

Group type: EXPERIMENTAL
Intervention: Infusion group (pantoprazole 80 mg i.v. bolus followed by continuous infusion of 8 mg/h for 3 days)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Bolus group (pantoprazole 80 mg i.v. bolus followed by 40 mg i.v. bolus every 12 h for 3 days)
Number of subjects: 168

Group type: COMPARATOR
Intervention: No-treatment group (no acid suppression in the first 3 days)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Infusion group vs Bolus group
Number of subjects: 168
Study: 15138759

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 11266685

Group type: COMPARATOR
Intervention: Magnetisation transfer ratio (MTR) histogram analysis in primary progressive MS patients
Number of subjects: 122

Group type: COMPARATOR
Intervention: Magnetisation transfer ratio (MTR) histogram analysis in disabled relapsing onset patients
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Principal component (PC) analysis of MTR histogram
Number of subjects: 122

Group type: COMPARATOR
Intervention: Magnetisation transfer ratio (MTR) histogram analysis in benign and nondisabled relapsing onset patients
Number of subjects: 122
Study: 9885014

Group type: EXPERIMENTAL
Intervention: Normal pregnancy cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPL cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early normal pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPL
Number of subjects: 0
Study: 7791015

Group type: EXPERIMENTAL
Intervention: Intracervical 0.5 mg PGE2 gel
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Intravaginal 3 mg PGE2 tablet
Number of subjects: 467
Study: 3278823

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30916733

Group type: EXPERIMENTAL
Intervention: Drug-deactivation bag
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care or disposal information sheet
Number of subjects: 0
Study: 29176768

Group type: EXPERIMENTAL
Intervention: Open administration of expressive writing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hidden administration of expressive writing intervention
Number of subjects: 0
Study: 25961456

Group type: EXPERIMENTAL
Intervention: Notch signaling activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of Notch signaling (genetic or pharmacological approaches)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Notch pathway activity (elevated)
Number of subjects: 0
Study: 23514584

Group type: EXPERIMENTAL
Intervention: Temsirolimus monotherapy (25 mg weekly)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination therapy (irinotecan 180 mg/m2 biweekly + temsirolimus)
Number of subjects: 64
Study: 18193579

Group type: EXPERIMENTAL
Intervention: Cortexin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nootropil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cerebrolysin
Number of subjects: 80
Study: 14566709

Group type: EXPERIMENTAL
Intervention: Guided imagery intervention (audiotaped)
Number of subjects: 62
Study: 10569465

Group type: EXPERIMENTAL
Intervention: Office dust exposure (439 microg/m3)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clean air exposure (17 microg/m3)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bronchial provocation with histamine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nasal mucosal swelling
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Eye irritation tests (threshold for eye irritation with carbon dioxide, eye redness, cellular content of conjunctival fluid)
Number of subjects: 23
Study: 8915019

Group type: EXPERIMENTAL
Intervention: Tetracycline HCl loaded ethylene vinyl acetate co‐polymer fiber placed into the periodontal pocket of 1 randomly selected tooth
Number of subjects: 35

Group type: COMPARATOR
Intervention: No further treatment on a non-adjacent tooth with persistent or recurrent periodontitis
Number of subjects: 35
Study: 1856141

Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg/day given as a single dose
Number of subjects: 220

Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg/day given in two divided doses at 12‐h intervals
Number of subjects: 220
Study: 6349646

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium, 200 mg/day
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium, 300 mg/day
Number of subjects: 757

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 757

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA), 3.6 g/day
Number of subjects: 757
Study: 29947474

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg orally disintegrating film
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sildenafil 50 mg film-coated tablets (Viagra®, Pfizer, Mexico)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 47
Study: 28438118

Group type: EXPERIMENTAL
Intervention: Lowenstein-Jensen (LJ) culture method
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mycobacteria growth indicator tube (MGIT) culture method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rifampicin-based regimens (R10, 15 and 20 mg/Kg)
Number of subjects: 100
Study: 26412308

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) alone
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate (GTN) alone
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) + Glyceryl Trinitrate (GTN)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Neither RIC nor GTN (sham RIC)
Number of subjects: 260
Study: 24050454

Group type: EXPERIMENTAL
Intervention: Repositioning every 2 hours
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Repositioning every 3 hours
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Repositioning every 4 hours
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: High-risk participants (repositioning schedule)
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Moderate-risk participants (repositioning schedule)
Number of subjects: 942

Group type: COMPARATOR
Intervention: Overall comparison of repositioning groups
Number of subjects: 942

Group type: COMPARATOR
Intervention: Overall comparison of risk groups
Number of subjects: 942
Study: 22319956

Group type: EXPERIMENTAL
Intervention: Self-verbalization group (n=18)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Experimenter-verbalization group (n=21)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-verbalization control group (n=17)
Number of subjects: 56
Study: 19247202

Group type: EXPERIMENTAL
Intervention: CIFN induction therapy (27 or 18 mg q.d.)
Number of subjects: 217
Study: 17084191

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic motor‐evoked potentials (tcMMEPs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dermatomal somatosensory‐evoked potentials (d‐SSEPs)
Number of subjects: 20